



## Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

February 20, 2024

WALTHAM, Mass., Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2023 financial results and provide a business update on Tuesday, February 27, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, February 27, 2024 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the [Events & Presentations page](#) in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax4Q23

Domestic Dial-in Number: 800-590-8290

International Dial-in Number: 240-690-8800

Live webcast: <https://www.veracast.com/webcasts/syndax/events/SNDX4Q23.cfm>

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at [www.syndax.com](http://www.syndax.com) approximately 24 hours after the conference call and will be available for 90 days following the call.


### About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin-KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [Twitter](#) and [LinkedIn](#).

### Syndax Contact

Sharon Klahre  
Syndax Pharmaceuticals, Inc.  
[sklahre@syndax.com](mailto:sklahre@syndax.com)  
Tel 781.684.9827

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2023-financial-results-and-host-conference-call-and-webcast-on-february-27-2024-302066595.html>

SOURCE Syndax Pharmaceuticals, Inc.